BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.Full text not available from this repository.
A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of .gamma.-linolenoyl, dihomo-.gamma.-linolenoyl acid and arachidonoyl.
|Uncontrolled Keywords:||structured phospholipids, cytokines, multiple sclerosis|
|Subjects:||R Medicine > R Medicine (General)|
|School / Department / Research Groups:||School of Science > Department of Life & Sports Science
Faculty of Engineering & Science > School of Science > Department of Life & Sports Science
School of Science
Faculty of Engineering & Science > School of Science
|Last Modified:||07 Aug 2012 16:57|
Actions (login required)